The development of resistance to CDK4/6 inhibitors from both the pre-activation of the PI3K or MAPK pathway or compensatory activation is being explored extensively in breast cancer, and clearly warrants preclinical testing in pediatric and AYA sarcomas with CDK4/6 hyperactivation. Here, CDK4 is linked to breast cancer.